Marina Grandis

List of Publications by Year
in descending order

83	2,270	257450 24	233421 45
papers	citations	h-index	g-index

84	84	84	2603
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phenotypic clustering in MPZ mutations. Brain, 2004, 127, 371-384.	7.6	257
2	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	10.2	193
3	Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain, 2005, 128, 1168-1177.	7.6	113
4	Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1166-1174.	1.9	99
5	Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M. Journal of the Peripheral Nervous System, 2007, 12, 102-107.	3.1	98
6	Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1314-1321.	5.3	82
7	Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Journal of Neurology, 2016, 263, 916-924.	3.6	76
8	MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients. Orphanet Journal of Rare Diseases, 2016, 11, 91.	2.7	70
9	Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Human Molecular Genetics, 2008, 17, 1877-1889.	2.9	69
10	RFC1 expansions are a common cause of idiopathic sensory neuropathy. Brain, 2021, 144, 1542-1550.	7.6	63
11	HSPB1 and HSPB8 in inherited neuropathies: study of an Italian cohort of dHMN and CMT2 patients. Journal of the Peripheral Nervous System, 2011, 16, 287-294.	3.1	57
12	Mycophenolate mofetil in dysimmune neuropathies: A preliminary study. Muscle and Nerve, 2004, 29, 748-749.	2.2	51
13	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	3.0	51
14	Major myelin protein gene (P0) mutation causes a novel form of axonal degeneration. Journal of Comparative Neurology, 2006, 498, 252-265.	1.6	49
15	Nerve conduction velocity in <scp>CMT</scp>1A: what else can we tell?. European Journal of Neurology, 2016, 23, 1566-1571.	3.3	45
16	Inherited Neuropathies. Current Treatment Options in Neurology, 2011, 13, 160-179.	1.8	44
17	Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. Journal of Neurology, 2021, 268, 189-198.	3.6	38
18	Clinical features and molecular modelling of novel MPZ mutations in demyelinating and axonal neuropathies. European Journal of Human Genetics, 2009, 17, 1129-1134.	2.8	35

#	Article	IF	Citations
19	Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease. Neurobiology of Disease, 2004, 16, 263-273.	4.4	34
20	Outcome Measures and Rehabilitation Treatment in Patients Affected by Charcot-Marie-Tooth Neuropathy. American Journal of Physical Medicine and Rehabilitation, 2011, 90, 628-637.	1.4	34
21	Very High Prevalence of Right-to-Left Shunt on Transcranial Doppler in an Italian Family with Cerebral Autosomal Dominant Angiopathy with Subcortical Infarcts and Leukoencephalopathy. European Neurology, 2001, 46, 198-201.	1.4	32
22	Severe Neuropathy After Diphtheria-Tetanus-Pertussis Vaccination in a Child Carrying a Novel Frame-Shift Mutation in the Small Heat-Shock Protein 27 Gene. Journal of Child Neurology, 2010, 25, 107-109.	1.4	32
23	Relapses After Treatment With Rituximab in a Patient With Multiple Sclerosis and Antiâ€“Myelin-Associated Glycoprotein Polyneuropathy. Archives of Neurology, 2007, 64, 1531.	4.5	30
24	The D355V Mutation Decreases EGR2 Binding to an Element within the Cx32 Promoter. Neurobiology of Disease, 2001, 8, 700-706.	4.4	27
25	Current therapy for Charcot-Marie-Tooth disease. Current Treatment Options in Neurology, 2005, 7, 23-31.	1.8	24
26	hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers. Brain Sciences, 2020, 10, 780.	2.3	24
27	Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase. Acta Myologica, 2020, 39, 57-66.	1.5	24
28	PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. Annals of Neurology, 2001, 50, 47-55.	5.3	23
29	Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype. Journal of Neurology, 2019, 266, 2629-2645.	3.6	23
30	Parsonageâ€“Turner syndrome following coronavirus disease 2019 immunization with ChAdOx1-S vaccine:Âa case report and review of theÂliterature. Journal of Medical Case Reports, 2021, 15, 589.	0.8	22
31	Insulin treatment enhances expression of IGF-I in sural nerves of diabetic patients. Muscle and Nerve, 2001, 24, 622-629.	2.2	21
32	A novel mutation in KIF5A gene causing hereditary spastic paraplegia with axonal neuropathy. Neurological Sciences, 2011, 32, 665-668.	1.9	21
33	Gain of glycosylation: A new pathomechanism of myelin protein zero mutations. Annals of Neurology, 2012, 71, 427-431.	5.3	20
34	Treadmill training in patients affected by Charcotâ€“Marieâ€“Tooth neuropathy: results of a multicenter, prospective, randomized, singleâ€blind, controlled study. European Journal of Neurology, 2020, 27, 280-287.	3.3	19
35	Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. Experimental Neurology, 2004, 190, 213-223.	4.1	18
36	GDAP1 mutations in Italian axonal Charcotâ€“Marieâ€“Tooth patients: Phenotypic features and clinical course. Neuromuscular Disorders, 2016, 26, 26-32.	0.6	18

#	Article	IF	Citations
37	Impaired Expression of Ciliary Neurotrophic Factor in Charcot-Marie-Tooth Type 1A Neuropathy. Journal of Neuropathology and Experimental Neurology, 2009, 68, 441-455.	1.7	17
38	The spectrum of GNE mutations: allelic heterogeneity for a common phenotype. Neurological Sciences, 2010, 31, 377-380.	1.9	17
39	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	3.1	17
40	The suspected SARS-Cov-2 infection in a Charcot-Marie-Tooth patient undergoing postsurgical rehabilitation: the value of telerehabilitation for evaluation and continuing treatment. International Journal of Rehabilitation Research, 2020, 43, 285-286.	1.3	17
41	Influence of comorbidities on the phenotype of patients affected by Charcotâ€“Marieâ€“Tooth neuropathy type 1A. Neuromuscular Disorders, 2013, 23, 902-906.	0.6	15
42	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <scp>PATH</scp> study and a systematic review. Journal of the Peripheral Nervous System, 2020, 25, 230-237.	3.1	15
43	Gap junction beta 1 (GJB1) gene mutations in Italian patients with X-linked Charcot-Marie-Tooth disease. Journal of Human Genetics, 2008, 53, 529-533.	2.3	13
44	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	3.1	13
45	Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. Journal of Neurology, 2022, 269, 1905-1912.	3.6	13
46	Realâ€life experience with inotersen in hereditary transthyretin amyloidosis with lateâ€onset phenotype: Data from an earlyâ€access program in Italy. European Journal of Neurology, 2022, 29, 2148-2155.	3.3	13
47	Glycans of myelin proteins. Journal of Neuroscience Research, 2015, 93, 1-18.	2.9	12
48	Diagnostic Value of Sural Nerve Biopsy: Retrospective Analysis of Clinical Cases From 1981 to 2017. Frontiers in Neurology, 2019, 10, 1218.	2.4	12
49	High-Dose Intravenous Immunoglobulin Is Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. Pain Medicine, 2020, 21, 576-585.	1.9	11
50	Pregnancy in Charcot-Marie-Tooth disease. Neurology, 2020, 95, e3180-e3189.	1.1	11
51	Guillain-BarrÃ© syndrome following chickenpox: a case series. International Journal of Neuroscience, 2016, 126, 478-479.	1.6	10
52	A novel mutation in the N-terminal acting-binding domain of Filamin C protein causing a distal myofibrillar myopathy. Journal of the Neurological Sciences, 2019, 398, 75-78.	0.6	10
53	Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study. Journal of Clinical Medicine, 2020, 9, 3454.	2.4	10
54	An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic <scp>hyperCKemia</scp>. Muscle and Nerve, 2022, 65, 96-104.	2.2	10

#	Article	IF	Citations
55	Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine. Human Vaccines and Immunotherapeutics, 2014, 10, 1969-1973.	3.3	9
56	Innovative quantitative testing of hand function inÂCharcotâ€Marieâ€Tooth neuropathy. Journal of the Peripheral Nervous System, 2015, 20, 410-414.	3.1	8
57	Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet Journal of Rare Diseases, 2021, 16, 163.	2.7	8
58	Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature. Neurological Sciences, 2021, 42, 1405-1409.	1.9	7
59	High-dose immunoglobulin pulse therapy and risk of Covid19 infection. Journal of Neurology, 2021, 268, 1573-1575.	3.6	7
60	Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis. Journal of		

#	Article	IF	Citations
73	Screening for Fabry disease in unknown origin axonal polyneuropathy: to do or not to do, this is the question!. Orphanet Journal of Rare Diseases, 2020, 15, 216.	2.7	2
74	Charcot-Marie-Tooth neuropathy score and ambulation index are both predictors of orthotic need for patients with CMT. Neurological Sciences, 2022, 43, 2759-2764.	1.9	2
75	An eleven-year history of Vanishing White Matter Disease in an adult patient with no cognitive decline and EIF2B5 mutations. A case report. Neurocase, 2021, 27, 452-456.	0.6	2
76	Maintenance treatment with subcutaneous immunoglobulins in the long-term management of anti-HMCGR myopathy. Neuromuscular Disorders, 2021, 31, 134-138.	0.6	1
77	Feasibility of imaging phenotyping (radiomics) on nuclear MRI of major lower limb nerves. Journal of Radiological Review, 2019, 6, .	0.1	1
78	The primary role of radiological imaging in the diagnosis of rare musculoskeletal diseases. Emphasis on ultrasound. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ‚-SzopiÅ„ska, 2019, 19, 187-192.	1.2	1
79	Comparison of Strength and Dexterity in Professional and Student Violinists: Setting Foundations to Guide Rehabilitation. Medical Problems of Performing Artists, 2020, 35, 130-137.	0.4	1
80	Intravenous versus subcutaneous immunoglobulin â€“ Authors' reply. Lancet Neurology, The, 2018, 17, 393-394.	10.2	0
81	Response to Dr. Wee. Pain Medicine, 2020, 21, 2604-2604.	1.9	0
82	6MWT as measure of motor function and endurance in SMA type 3 patients treated with nusinersen. Journal of the Neurological Sciences, 2021, 429, 119385.	0.6	0
83	How to define and enhance diagnostic and assistance pathways in neuromuscular diseases during the COVID-19 pandemic: the concept of network.. Acta Myologica, 2021, 40, 172-176.	1.5	0